| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/120454WO2019127607A1 (en) | 2017-12-31 | 2017-12-31 | A conjugate of a tubulysin analog with branched linkers |
| Publication Number | Publication Date |
|---|---|
| MX2020006192Atrue MX2020006192A (en) | 2020-08-20 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006192AMX2020006192A (en) | 2017-12-31 | 2017-12-31 | A CONJUGATE OF A TUBULISIN ANALOG WITH BRANCHED LINKERS. |
| Country | Link |
|---|---|
| US (4) | US11998584B2 (en) |
| EP (1) | EP3621652A4 (en) |
| JP (2) | JP7262817B2 (en) |
| KR (2) | KR102641565B1 (en) |
| CN (1) | CN111093707A (en) |
| AU (2) | AU2017445144A1 (en) |
| BR (1) | BR112020010405A2 (en) |
| CA (1) | CA3085634C (en) |
| CL (1) | CL2020001600A1 (en) |
| EA (1) | EA202091217A1 (en) |
| IL (2) | IL317268A (en) |
| MX (1) | MX2020006192A (en) |
| PH (1) | PH12020550657A1 (en) |
| SG (1) | SG11202004801WA (en) |
| WO (1) | WO2019127607A1 (en) |
| ZA (1) | ZA202003211B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012385228B2 (en) | 2012-07-12 | 2016-10-06 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
| US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| BR112020010405A2 (en) | 2017-12-31 | 2020-11-24 | Hangzhou Dac Biotech Co., Ltd | side-chain-connected and side-chain-connecting conjugate compounds, side chains q1 and q2, d (tubulisin structure), w, l1, l2, v1 and v2, cell binding agent/molecule, tumor cell, pharmaceutical composition , and, chemotherapeutic and synergistic agents |
| WO2020132658A2 (en) | 2018-12-21 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| US20220249594A1 (en)* | 2019-06-24 | 2022-08-11 | Hangzhou Dac Biotech Co., Ltd | A formulation of a conjugate of a tubulysin analog to a cell-binding molecule |
| IL289134A (en)* | 2019-06-24 | 2022-07-01 | Hangzhou Dac Biotech Co Ltd | Conjugation of a cytotoxic factor to a cell-binding molecule with branched linkers |
| JP2022540395A (en)* | 2019-06-29 | 2022-09-15 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | Cell-binding molecule-tubulysin derivative conjugate and method for preparing the same |
| WO2021022678A1 (en)* | 2019-08-07 | 2021-02-11 | 烟台迈百瑞国际生物医药股份有限公司 | Antibody-drug conjugate and application thereof |
| AU2020407089B2 (en) | 2019-12-17 | 2023-06-01 | The Board Of Regents Of The University Of Texas System | Novel DDR1 antibodies and uses thereof |
| EP3862023A1 (en)* | 2020-02-05 | 2021-08-11 | Hangzhou DAC Biotech Co, Ltd | Conjugates of cell-binding molecules with cytotoxic agents |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| CA3174239A1 (en)* | 2020-05-08 | 2021-11-11 | Yousef Al-Abed | Dimers for use in synthesis of peptidomimetics |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| CN112138170B (en)* | 2020-09-28 | 2022-05-20 | 广东药科大学 | Conjugate for preventing cisplatin drug-induced deafness and preparation method and application thereof |
| CN112755173B (en)* | 2020-12-31 | 2022-01-07 | 深圳市科达顺生物技术有限公司 | Ii-Key/HER2 hybrid polypeptide drug for treating triple-negative breast cancer and preparation method thereof |
| CN112961060B (en)* | 2021-02-09 | 2022-03-25 | 武汉大学 | Isotope labeled N, N-dimethylethylenediamine, preparation method thereof and analysis method of short-chain fatty acid |
| KR20230170769A (en)* | 2021-04-14 | 2023-12-19 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | Linkers, conjugates and their applications |
| WO2022266354A1 (en)* | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napoli |
| WO2023036193A1 (en)* | 2021-09-08 | 2023-03-16 | 同宜医药（苏州）有限公司 | Pharmaceutical preparation, preparation method therefor and use thereof |
| EP4426727A2 (en)* | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| WO2023209625A1 (en)* | 2022-04-28 | 2023-11-02 | Scirosbio (Fzc) | Compositions and methods for treatment of cancer |
| KR20250025418A (en)* | 2022-06-17 | 2025-02-21 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Method and composition comprising tobacco green mosaic virus (TMGMV) |
| AU2023448948A1 (en)* | 2023-05-24 | 2025-10-09 | Hangzhou Dac Biotech Co., Ltd | Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate |
| WO2025021118A1 (en)* | 2023-07-25 | 2025-01-30 | 海南先声再明医药股份有限公司 | Ligand-drug conjugate and linker for conjugation |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004005326A2 (en) | 2002-07-09 | 2004-01-15 | Morphochem Aktiengellschaft Fu | Tubulysin conjugates |
| EP2139523B1 (en) | 2007-03-14 | 2014-10-22 | Endocyte, Inc. | Conjugates of folate and tubulysin for targeted drug delivery |
| AU2012385228B2 (en)* | 2012-07-12 | 2016-10-06 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
| ES2701076T3 (en)* | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
| GB201402009D0 (en)* | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| CA2938919C (en) | 2014-02-28 | 2020-12-29 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
| CA2945318A1 (en)* | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Tubulysin derivatives |
| TW201617081A (en) | 2014-09-25 | 2016-05-16 | 安德賽特公司 | Methods of treating cancer with Tubulysin conjugates |
| CN110279872A (en)* | 2014-11-11 | 2019-09-27 | 杭州多禧生物科技有限公司 | Conjugated body of the cytotoxic molecule with cell bound receptor molecule |
| CA2989269C (en)* | 2015-06-15 | 2020-09-22 | Robert Yongxin Zhao | Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule |
| JP6817288B2 (en)* | 2015-08-10 | 2021-01-20 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | Its use in novel conjugates and specific conjugation of biomolecules with drugs |
| TWI814699B (en)* | 2015-12-04 | 2023-09-11 | 美商思進公司 | Conjugates of quaternized tubulysin compounds |
| EP3411074A4 (en) | 2016-02-04 | 2019-09-04 | Suzhou M-conj Biotech Co., Ltd. | SPECIFIC, IMMUNOCONJUGUATED CONJUGATION LINKS SPECIFIC THEREOF, METHODS OF MAKING AND USES OF SAID CONJUGATES THEREOF |
| KR102295190B1 (en)* | 2016-04-20 | 2021-08-30 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Derivatives of Amanita Toxin and Its Binding with Cell Binding Molecules |
| CA3042442C (en)* | 2016-11-14 | 2024-01-02 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers |
| MX2019011957A (en) | 2017-04-06 | 2019-11-07 | Hangzhou Dac Biotech Co Ltd | Conjugation of a cytotoxic drug with bis-linkage. |
| BR112020010405A2 (en) | 2017-12-31 | 2020-11-24 | Hangzhou Dac Biotech Co., Ltd | side-chain-connected and side-chain-connecting conjugate compounds, side chains q1 and q2, d (tubulisin structure), w, l1, l2, v1 and v2, cell binding agent/molecule, tumor cell, pharmaceutical composition , and, chemotherapeutic and synergistic agents |
| Publication number | Publication date |
|---|---|
| ZA202003211B (en) | 2024-04-24 |
| CA3085634A1 (en) | 2019-07-04 |
| US20230149502A1 (en) | 2023-05-18 |
| US20200276261A1 (en) | 2020-09-03 |
| WO2019127607A1 (en) | 2019-07-04 |
| JP2023093531A (en) | 2023-07-04 |
| EP3621652A4 (en) | 2021-01-13 |
| EA202091217A1 (en) | 2020-09-18 |
| KR20200097295A (en) | 2020-08-18 |
| BR112020010405A2 (en) | 2020-11-24 |
| IL275274A (en) | 2020-07-30 |
| NZ764814A (en) | 2024-02-23 |
| US11998584B2 (en) | 2024-06-04 |
| AU2022205269A1 (en) | 2022-08-11 |
| PH12020550657A1 (en) | 2021-04-19 |
| AU2017445144A1 (en) | 2020-06-18 |
| IL275274B2 (en) | 2025-05-01 |
| IL275274B1 (en) | 2025-01-01 |
| JP7262817B2 (en) | 2023-04-24 |
| EP3621652A1 (en) | 2020-03-18 |
| US20230165931A1 (en) | 2023-06-01 |
| JP2021507928A (en) | 2021-02-25 |
| IL317268A (en) | 2025-01-01 |
| US20230165930A1 (en) | 2023-06-01 |
| SG11202004801WA (en) | 2020-06-29 |
| JP7637431B2 (en) | 2025-02-28 |
| KR102603344B1 (en) | 2023-11-16 |
| AU2022205269B2 (en) | 2024-07-11 |
| KR20230075530A (en) | 2023-05-31 |
| CN111093707A (en) | 2020-05-01 |
| KR102641565B1 (en) | 2024-02-27 |
| CL2020001600A1 (en) | 2021-03-19 |
| CA3085634C (en) | 2023-11-14 |
| Publication | Publication Date | Title |
|---|---|---|
| ZA202003211B (en) | A conjugate of a tubulysin analog with branched linkers | |
| MX2021009147A (en) | A CONJUGATE OF AN AMATOXIN ANALOG WITH BRANCHED LINKERS. | |
| PH12019502278A1 (en) | Conjugation of a cytotoxic drug with bis-linkage | |
| MX2023013592A (en) | Drug conjugates with self-stabilizing linkers having improved physiochemical properties. | |
| PH12021500050A1 (en) | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers | |
| MX2018006218A (en) | Conjugates of quaternized tubulysin compounds. | |
| MX2020010458A (en) | Camptothecin peptide conjugates. | |
| EA201590622A1 (en) | CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION | |
| MX2019010804A (en) | Benzazepine compounds, conjugates, and uses thereof. | |
| EA201201400A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | |
| EA201790404A1 (en) | MACROPINOCYTOZING HUMAN ANTI-CD46 ANTIBODIES AND TARGET TREATMENT OF CANCER | |
| EP4306538A3 (en) | Peptide oligonucleotide conjugates | |
| MY171100A (en) | Anti-ceacam5 antibodies and uses thereof | |
| BR112021025699A2 (en) | Anti-mesothelin antibodies and immunoconjugates thereof | |
| PH12022550494A1 (en) | Therapeutic conjugates | |
| WO2011103567A3 (en) | Peptides and methods for inducing cell death | |
| EA201591758A1 (en) | Sub-ADAMTS13 INTRODUCTION | |
| MX2022014231A (en) | ANTIBODY-DRUG CONJUGATES TARGETING uPARAP. | |
| MX2020003089A (en) | Thailanstatin analogs. | |
| CY1123818T1 (en) | SYD985 TREATMENT OF T-DM1 DEFICIENCY IN CANCER PATIENTS | |
| ZA202101990B (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| EA202190457A1 (en) | CONJUGATES FOR USE IN METHODS FOR TREATMENT OF CANCER | |
| EA202092369A1 (en) | PHOSPHOLIPID-FLAVAGLIN CONJUGATES AND METHODS FOR THEIR APPLICATION FOR TARGETED CANCER THERAPY | |
| PH12016502042A1 (en) | Drug delivery conjugates for treating resistant cancer and for use in combination therapy | |
| EP4592307A3 (en) | A sensitizer - peptide conjugate |